サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1376086

心血管臨床試験の市場規模、シェア、動向分析レポート：フェーズ別、研究デザイン別、適応症別、地域別、セグメント予測、2023年～2030年

Cardiovascular Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication, By Region, & Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 195 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
心血管臨床試験の市場規模、シェア、動向分析レポート：フェーズ別、研究デザイン別、適応症別、地域別、セグメント予測、2023年～2030年
出版日: 2023年10月11日
発行: Grand View Research
ページ情報: 英文 195 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

心血管臨床試験市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の心血管臨床試験市場規模は、2023年から2030年にかけてCAGR 6.0％を記録し、2030年までに84億1,000万米ドルに達すると予測されています。

市場の成長は主に、心不全、脳卒中、冠動脈疾患などの心血管疾患の有病率の増加によるものです。さらに、個別化医療やゲノミクスを含む医学研究の絶え間ない進歩が、新規戦略や治療法を調査するための臨床試験の必要性を煽っています。さらに、バーチャル臨床試験の採用や臨床試験患者の遠隔モニタリングなど、臨床研究における技術革新は、より費用対効果が高く効率的な臨床試験管理を促進し、市場の成長を支えています。

市場は断片化されており、複数の企業が同様の技術力と処理能力を有しています。複数の開発業務受託機関が心血管臨床試験の分野に参入しています。さらに、これらの企業は新規化合物に関する実験を行い、心血管治療療法の革新に注力しています。これらの企業は、市場での存在感を高めるために、バイオ製薬企業との提携や協力に注力しています。例えば、2023年8月、臨床研究機関であるDr. Vince Clinical Research（DVCR）は、臨床試験における心臓評価を提供するためのクラリオとの戦略的提携を発表しました。

さらに、臨床試験の世界化も市場の成長を支える重要な要因です。例えば、2022年5月の臨床試験アリーナによると、中国で実施される臨床試験への欧米の営利企業の関与は、2010年の年間約100件から徐々に増加し、2021年には約350件に達しています。したがって、これは予測期間中の市場成長を支える主な要因の一つです。

COVID-19パンデミックは市場にマイナスの影響を与えました。COVID-19パンデミックの初期段階は、心血管を適応症とする試験を含む渡航制限により臨床試験に大きな影響を与えました。しかし、仮想臨床試験や分散型臨床試験といった新しい試験方法を採用することにより、市場は回復しました。

心血管臨床試験市場レポートハイライト

  • フェーズに基づくと、フェーズIVセグメントが2022年に34.3%の最大シェアを占めました。このセグメントを牽引するのは、新規治療薬に対する需要の高まりと、市販後調査プロセスの評価強化のために実臨床データを取り入れることです。
  • 試験デザインに基づくと、介入型セグメントは2022年に64.8%の最大シェアを占めました。このセグメントシェアが高い主な理由は、管理された介入型臨床試験で心血管治療薬のパイプラインが増加しているためです。
  • 適応症別に見ると、脳卒中分野は、世界の有病率の上昇と革新的な脳卒中治療に対するニーズの急増により、分析期間を通じて6.9%のCAGRが見込まれます。
  • アジア太平洋地域は、予測期間中に6.8%のCAGRを記録すると予測されています。高い成長は主に、中国やインドなどの新興経済諸国に製造活動をアウトソーシングする欧米の製薬企業の増加によるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 心血管臨床試験市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 心血管臨床試験市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19感染症の影響分析

第4章 心血管臨床試験市場：フェーズの推定・動向分析

  • 心血管臨床試験市場、フェーズ別：セグメントダッシュボード
  • 心血管臨床試験市場、フェーズ別：変動分析

第5章 心血管臨床試験市場：研究デザインの推定・動向分析

  • 心血管臨床試験市場、研究デザイン別：セグメントダッシュボード
  • 心血管臨床試験市場、研究デザイン別：変動分析

第6章 心血管臨床試験市場：適応症の推定と推定・動向分析

  • 心血管臨床試験市場、適応症別：セグメントダッシュボード
  • 心血管臨床試験市場、適応症別：変動分析

第7章 心血管臨床試験市場：地域の推定・動向分析

  • 地域市場シェア分析、2022年および2030年
  • 地域市場ダッシュボード
  • 世界の地域市場のスナップショット
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • 日本
    • インド
    • 中国
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 市場参入企業の分類
    • イノベーター
    • マーケットリーダー
    • 新興プレイヤー
    • 企業の市場シェア分析、2022年
  • 企業プロファイル
    • IQVIA Inc
    • ICON plc
    • SGS SA
    • Eli Lilly and Company
    • PPD Inc
    • Syneos Health
    • Caidya
    • Worldwide Clinical Trials
    • Vial
    • Veeda Clinical Research
    • Medpace, Inc.
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 North America Cardiovascular Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 4 North America Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 5 North America Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 6 North America Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 7 U.S. Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 8 U.S. Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 9 U.S. Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 10 Canada Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 11 Canada Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 12 Canada Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 13 Europe Cardiovascular Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 14 Europe Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 15 Europe Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 16 Europe Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 17 UK Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 18 UK Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 19 UK Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 20 Germany Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 21 Germany Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 22 Germany Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 23 France Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 24 France Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 25 France Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 26 Italy Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 27 Italy Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 28 Italy Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 29 Spain Cardiovascular Clinical Trials market, by Study Design type, 2018 - 2030 (USD Million)
  • Table 30 Spain Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 31 Spain Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 32 Denmark Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 33 Denmark Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 34 Denmark Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 35 Sweden Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 36 Sweden Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 37 Sweden Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 38 Norway Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 39 Norway Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 40 Norway Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Cardiovascular Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 45 China Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 46 China Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 47 China Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 48 Japan Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 49 Japan Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 50 Japan Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 51 India Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 52 India Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 53 India Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 54 Australia Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 55 Australia Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 56 Australia Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 57 South Korea Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 58 South Korea Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 59 South Korea Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 60 Thailand Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 61 Thailand Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 62 Thailand Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 63 Latin America Cardiovascular Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 64 Latin America Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 65 Latin America Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 66 Latin America Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 67 Brazil Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 68 Brazil Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 69 Brazil Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 70 Mexico Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 71 Mexico Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 72 Mexico Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 73 Argentina Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 74 Argentina Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 75 Argentina Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 76 Middle East and Africa Cardiovascular Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 77 Middle East and Africa Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 78 Middle East and Africa Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 79 Middle East and Africa Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 80 South Africa Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 81 South Africa Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 82 South Africa Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 86 UAE Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 87 UAE Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 88 UAE Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 91 Kuwait Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modeling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Primary research pattern
  • Fig. 8 Primary interviews in North America
  • Fig. 9 Primary Interviews in Europe
  • Fig. 10 Primary interviews in Asia Pacific
  • Fig. 11 Primary interviews in Latin America
  • Fig. 12 Primary interviews in MEA
  • Fig. 13 Market Snapshot
  • Fig. 14 Segment Snapshot
  • Fig. 15 Segment Snapshot
  • Fig. 16 Competitive Landscape Snapshot
  • Fig. 17 Cardiovascular Clinical Trials Market Segmentation
  • Fig. 18 Parent market outlook (2022)
  • Fig. 19 Related/ancillary market outlook (2022)
  • Fig. 20 Market driver relevance analysis (Current & future impact)
  • Fig. 21 Current shared services and outsourcing usage levels
  • Fig. 22 Market restraint relevance analysis (Current & future impact)
  • Fig. 23 Porter's Five Forces analysis
  • Fig. 24 SWOT analysis, by a factor (political & legal, economic and technological)
  • Fig. 25 Cardiovascular Clinical Trials Market Phase outlook: Segment dashboard
  • Fig. 26 Cardiovascular Clinical Trials: Phase movement analysis
  • Fig. 27 Phase I market, 2018 - 2030 (USD Million)
  • Fig. 28 Phase II market, 2018 - 2030 (USD Million)
  • Fig. 29 Phase III market, 2018 - 2030 (USD Million)
  • Fig. 30 Phase IV market, 2018 - 2030 (USD Million)
  • Fig. 31 Cardiovascular Clinical Trials Market Study Design Outlook: Segment dashboard
  • Fig. 32 Cardiovascular Clinical Trials: Study Design type movement analysis
  • Fig. 33 Interventional market, 2018 - 2030 (USD Million)
  • Fig. 34 Observational market, 2018 - 2030 (USD Million)
  • Fig. 35 Expanded Access market, 2018 - 2030 (USD Million)
  • Fig. 36 Cardiovascular Clinical Trials market Indication outlook: Segment dashboard
  • Fig. 37 Cardiovascular Clinical Trials market: Indication movement analysis
  • Fig. 38 Acute Coronary Syndrome market, 2018 - 2030 (USD Million)
  • Fig. 39 Coronary Artery Disease market, 2018 - 2030 (USD Million)
  • Fig. 40 Ischemic Heart Disease market, 2018 - 2030 (USD Million)
  • Fig. 41 Pulmonary Arterial Hypertension market, 2018 - 2030 (USD Million)
  • Fig. 42 Stroke market, 2018 - 2030 (USD Million)
  • Fig. 43 Cardiac Arrhythmias market, 2018 - 2030 (USD Million)
  • Fig. 44 Heart Failure market, 2018 - 2030 (USD Million)
  • Fig. 45 Others market, 2018 - 2030 (USD Million)
  • Fig. 46 Regional marketplace: Segment dashboard
  • Fig. 47 Regional outlook, 2022 & 2030
  • Fig. 48 North America market, 2018 - 2030 (USD Million)
  • Fig. 49 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 50 Canada market, 2018 - 2030 (USD Million)
  • Fig. 51 Europe market, 2018 - 2030 (USD Million)
  • Fig. 52 Germany market, 2018 - 2030 (USD Million)
  • Fig. 53 UK market, 2018 - 2030 (USD Million)
  • Fig. 54 France market, 2018 - 2030 (USD Million)
  • Fig. 55 Italy market, 2018 - 2030 (USD Million)
  • Fig. 56 Spain market, 2018 - 2030 (USD Million)
  • Fig. 57 Denmark market, 2018 - 2030(USD Million)
  • Fig. 58 Sweden market, 2018 - 2030 (USD Million)
  • Fig. 59 Norway market, 2018 - 2030 (USD Million)
  • Fig. 60 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 61 China market, 2018 - 2030 (USD Million)
  • Fig. 62 Japan market, 2018 - 2030 (USD Million)
  • Fig. 63 India market, 2018 - 2030 (USD Million)
  • Fig. 64 Australia market, 2018 - 2030 (USD Million)
  • Fig. 65 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 66 Thailand market, 2018 - 2030 (USD Million)
  • Fig. 67 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 68 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 69 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 70 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 71 Middle East & Africa market, 2018 - 2030 (USD Million)
  • Fig. 72 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 74 UAE market, 2018 - 2030 (USD Million)
  • Fig. 75 Kuwait market, 2018 - 2030 (USD Million) 
目次
Product Code: GVR-4-68040-135-0

Cardiovascular Clinical Trials Market Growth & Trends:

The global cardiovascular clinical trials market size is expected to reach USD 8.41 billion by 2030, registering a CAGR of 6.0% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market's growth is majorly due to the increasing prevalence of cardiovascular diseases such as heart failure, stroke, and coronary artery diseases. Furthermore, the persistent advancements in medical research, including personalized medicine and genomics, fuel the need for clinical trials to investigate novel strategies and therapies. In addition, technological innovations in clinical research, such as the adoption of virtual clinical trials and remote monitoring of clinical trial patients, facilitate more cost-effective and efficient clinical trial management, thus supporting the growth of the market.

The market is fragmented, with several players having similar technological and processing capabilities. Several contract research organizations are penetrating the space of cardiovascular clinical trials. Moreover, these companies are focusing on innovating cardiovascular treatment therapies with experimentation over novel compounds. These players focus on partnerships and collaborations with bio-pharmaceutical companies to enhance their market presence. For instance, in August 2023, Dr. Vince Clinical Research (DVCR); a clinical research organization, announced a strategic alliance with Clario for delivering cardiac assessments in clinical trials.

Furthermore, the globalization of clinical trials is another significant factor supporting the market's growth. For instance, in May 2022, according to the clinical trials arena, the involvement of Western commercial companies in trials run in China has grown gradually from around 100 trials per year in 2010 to around 350 trials in 2021. Hence, this is one of the primary factors supporting the market growth during the forecast period.

The COVID-19 pandemic negatively impacted the market. The initial phase of the COVID-19 pandemic has significantly affected clinical trials due to travel restrictions, including trials involving cardiovascular indications. However, the market recovered by adopting novel trial methods such as virtual and decentralized clinical trials.

Cardiovascular Clinical Trials Market Report Highlights:

  • Based on phase, the Phase IV segment accounted for the largest share of 34.3% in 2022. The segment is driven by the growing demand for novel therapeutics and the incorporation of real-world data for enhanced assessment of the post-marketing surveillance process
  • Based on the study design, the interventional segment accounted for the largest share of 64.8% in 2022. High segment shares are majorly due to the growing pipeline of cardiovascular therapeutics under controlled interventional clinical trials
  • Based on indication, the stroke segment is anticipated to witness the highest CAGR of 6.9% across the analysis timeframe due to the increasing prevalence rate of the condition globally and the surge in the need for innovative stroke treatment therapies
  • Asia Pacific is anticipated to witness the highest CAGR of 6.8% during the forecast time frame. High growth is primarily due to the increasing number of Western pharmaceutical companies outsourcing their manufacturing activities to developing economies such as China and India

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
    • 1.1.2. Phase
    • 1.1.3. Study Design
    • 1.1.4. Indication
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. List Of Secondary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Cardiovascular Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising burden of cardiovascular diseases globally
      • 3.2.1.2. Globalization of clinical trials
      • 3.2.1.3. Increasing R&D expenditure towards clinical trials
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Rigorous approval standards set by regulatory bodies
      • 3.2.2.2. Patient recruitment and retention challenges
  • 3.3. Cardiovascular Clinical Trials Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat Of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Cardiovascular Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Cardiovascular Clinical Trials Market, By Phase: Segment Dashboard
  • 4.2. Cardiovascular Clinical Trials Market, By Phase: Movement Analysis
  • 4.3. Cardiovascular Clinical Trials Market Estimates & Forecasts, By Phase, 2018 - 2030
    • 4.3.1. Phase I
      • 4.3.1.1. Phase I Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
    • 4.3.2. Phase II
      • 4.3.2.1. Phase II Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
    • 4.3.3. Phase III
      • 4.3.3.1. Phase III Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
    • 4.3.4. Phase IV
      • 4.3.4.1. Phase IV Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)

Chapter 5. Cardiovascular Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. Cardiovascular Clinical Trials Market, By Study Design: Segment Dashboard
  • 5.2. Cardiovascular Clinical Trials Market, By Study Design: Movement Analysis
  • 5.3. Cardiovascular Clinical Trials Market Estimates & Forecasts, By Study Design, 2018 - 2030
    • 5.3.1. Interventional
      • 5.3.1.1. Interventional Cardiovascular Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.2. Observational
      • 5.3.2.1. Observational Cardiovascular Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.3. Expanded Access
      • 5.3.3.1. Expanded Access Cardiovascular Clinical Trials Market, 2018 to 2030 (USD Million)

Chapter 6. Cardiovascular Clinical Trials Market: Indication Estimates & Trend Analysis

  • 6.1. Cardiovascular Clinical Trials Market, By Indication: Segment Dashboard
  • 6.2. Cardiovascular Clinical Trials Market, By Indication: Movement Analysis
  • 6.3. Cardiovascular Clinical Trials Market Estimates & Forecasts, By Indication, 2018 - 2030
    • 6.3.1. Acute Coronary Syndrome
      • 6.3.1.1. Acute Coronary Syndrome Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)
    • 6.3.2. Coronary Artery Disease
      • 6.3.2.1. Coronary Artery Disease Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)
    • 6.3.3. Ischemic Heart Disease
      • 6.3.3.1. Ischemic Heart Disease Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)
    • 6.3.4. Pulmonary Arterial Hypertension
      • 6.3.4.1. Pulmonary Arterial Hypertension Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)
    • 6.3.5. Stroke
      • 6.3.5.1. Stroke Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)
    • 6.3.6. Cardiac Arrhythmias
      • 6.3.6.1. Cardiac Arrhythmias Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)
    • 6.3.7. Heart Failure
      • 6.3.7.1. Heart Failure Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)
    • 6.3.8. Others
      • 6.3.8.1. Others Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)

Chapter 7. Cardiovascular Clinical Trials Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2022 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. North America
    • 7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key Country Dynamics
      • 7.5.1.2. Competitive Scenario
      • 7.5.1.3. Regulatory Framework
      • 7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 7.5.2. Germany
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 7.5.3. France
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 7.5.4. Italy
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 7.5.5. Spain
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 7.5.6. Denmark
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 7.5.7. Sweden
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 7.5.8. Norway
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key Country Dynamics
      • 7.6.1.2. Competitive Scenario
      • 7.6.1.3. Regulatory Framework
      • 7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 7.6.2. India
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
    • 7.6.4. South Korea
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 7.6.6. Thailand
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key Country Dynamics
      • 7.7.1.2. Competitive Scenario
      • 7.7.1.3. Regulatory Framework
      • 7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 7.7.2. Mexico
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key Country Dynamics
      • 7.8.1.2. Competitive Scenario
      • 7.8.1.3. Regulatory Framework
      • 7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 7.8.3. UAE
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 7.8.4. Kuwait
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
    • 8.1.1. Innovators
    • 8.1.2. Market Leaders
    • 8.1.3. Emerging Players
    • 8.1.4. Company Market Share Analysis, 2022
  • 8.2. Company Profiles
    • 8.2.1. IQVIA Inc
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Financial Performance
      • 8.2.1.3. Service Benchmarking
      • 8.2.1.4. Strategic Initiatives
    • 8.2.2. ICON plc
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Financial Performance
      • 8.2.2.3. Service Benchmarking
      • 8.2.2.4. Strategic Initiatives
    • 8.2.3. SGS SA
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Financial Performance
      • 8.2.3.3. Service Benchmarking
      • 8.2.3.4. Strategic Initiatives
    • 8.2.4. Eli Lilly and Company
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Financial Performance
      • 8.2.4.3. Service Benchmarking
      • 8.2.4.4. Strategic Initiatives
    • 8.2.5. PPD Inc
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Financial Performance
      • 8.2.5.3. Service Benchmarking
      • 8.2.5.4. Strategic Initiatives
    • 8.2.6. Syneos Health
      • 8.2.6.1. Company Overview
      • 8.2.6.2. Financial Performance
      • 8.2.6.3. Service Benchmarking
      • 8.2.6.4. Strategic Initiatives
    • 8.2.7. Caidya
      • 8.2.7.1. Company Overview
      • 8.2.7.2. Financial Performance
      • 8.2.7.3. Service Benchmarking
      • 8.2.7.4. Strategic Initiatives
    • 8.2.8. Worldwide Clinical Trials
      • 8.2.8.1. Company Overview
      • 8.2.8.2. Financial Performance
      • 8.2.8.3. Service Benchmarking
      • 8.2.8.4. Strategic Initiatives
    • 8.2.9. Vial
      • 8.2.9.1. Company Overview
      • 8.2.9.2. Financial Performance
      • 8.2.9.3. Service Benchmarking
      • 8.2.9.4. Strategic Initiatives
    • 8.2.10. Veeda Clinical Research
      • 8.2.10.1. Company Overview
      • 8.2.10.2. Financial Performance
      • 8.2.10.3. Service Benchmarking
      • 8.2.10.4. Strategic Initiatives
    • 8.2.11. Medpace, Inc.
      • 8.2.11.1. Company Overview
      • 8.2.11.2. Financial Performance
      • 8.2.11.3. Service Benchmarking
      • 8.2.11.4. Strategic Initiatives